Edmond J. Safra Center for Ethics, Harvard University
Nonresident Fellow in Health Policy
High patented cancer drug prices are not related to the high cost of development or to the relative benefit of individual drugs over available ones. Several steps could be implemented to reduce these high prices to more acceptable ones.
Read the full article in Cancer.
